158 related articles for article (PubMed ID: 19753950)
1. Lack of follow-up of prostate-specific antigen test results.
McFall SL; Smith DW
Public Health Rep; 2009; 124(5):718-25. PubMed ID: 19753950
[TBL] [Abstract][Full Text] [Related]
2. National evidence on the use of shared decision making in prostate-specific antigen screening.
Han PK; Kobrin S; Breen N; Joseph DA; Li J; Frosch DL; Klabunde CN
Ann Fam Med; 2013; 11(4):306-14. PubMed ID: 23835816
[TBL] [Abstract][Full Text] [Related]
3. Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer.
Iyer HS; Stone BV; Roscoe C; Hsieh MC; Stroup AM; Wiggins CL; Schumacher FR; Gomez SL; Rebbeck TR; Trinh QD
JAMA Netw Open; 2024 Jun; 7(6):e2414582. PubMed ID: 38833252
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
5. Use of the prostate-specific antigen test among men aged 75 years or older in the United States: 2006 Behavioral Risk Factor Surveillance System.
Li J; Zhao G; Pollack LA; Smith JL; Joseph DA
Prev Chronic Dis; 2010 Jul; 7(4):A84. PubMed ID: 20550842
[TBL] [Abstract][Full Text] [Related]
6. Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006.
Ross LE; Taylor YJ; Richardson LC; Howard DL
J Natl Med Assoc; 2009 Apr; 101(4):316-24. PubMed ID: 19397221
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
8. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey.
Ross LE; Berkowitz Z; Ekwueme DU
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):636-44. PubMed ID: 18349281
[TBL] [Abstract][Full Text] [Related]
9. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
10. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?
Sirovich BE; Schwartz LM; Woloshin S
JAMA; 2003 Mar; 289(11):1414-20. PubMed ID: 12636464
[TBL] [Abstract][Full Text] [Related]
11. Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada.
Beaulac JA; Fry RN; Onysko J
Can J Public Health; 2006; 97(3):171-6. PubMed ID: 16827400
[TBL] [Abstract][Full Text] [Related]
12. Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006.
Zhu Y; Sorkin JD; Dwyer D; Groves C; Steinberger EK
Prev Chronic Dis; 2011 Sep; 8(5):A114. PubMed ID: 21843417
[TBL] [Abstract][Full Text] [Related]
13. Association of healthcare barriers with prostate-specific antigen screening among African-American and Afro-Caribbean men.
Lee DJ; Consedine NS; Gonzalez JR; Spencer BA
Urology; 2012 Sep; 80(3):556-63. PubMed ID: 22789295
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen screening among young men in the United States.
Scales CD; Antonelli J; Curtis LH; Schulman KA; Moul JW
Cancer; 2008 Sep; 113(6):1315-23. PubMed ID: 18696715
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.
Candas B; Cusan L; Gomez JL; Diamond P; Suburu RE; Lévesque J; Brousseau G; Bélanger A; Labrie F
Prostate; 2000 Sep; 45(1):19-35. PubMed ID: 10960839
[TBL] [Abstract][Full Text] [Related]
16. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program.
Cohen L; Fouladi RT; Babaian RJ; Bhadkamkar VA; Parker PA; Taylor CC; Smith MA; Gritz ER; Basen-Engquist K
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):610-7. PubMed ID: 12869399
[TBL] [Abstract][Full Text] [Related]
17. Shiftwork and prostate-specific antigen in the National Health and Nutrition Examination Survey.
Flynn-Evans EE; Mucci L; Stevens RG; Lockley SW
J Natl Cancer Inst; 2013 Sep; 105(17):1292-7. PubMed ID: 23943864
[TBL] [Abstract][Full Text] [Related]
18. Trends in prostate-specific antigen testing from 1995 through 2004.
Farwell WR; Linder JA; Jha AK
Arch Intern Med; 2007 Dec; 167(22):2497-502. PubMed ID: 18071173
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
[TBL] [Abstract][Full Text] [Related]
20. Circulating Prostate-Specific Antigen and Telomere Length in a Nationally Representative Sample of Men Without History of Prostate Cancer.
Wulaningsih W; Astuti Y; Matsuguchi T; Anggrandariyanny P; Watkins J;
Prostate; 2017 Jan; 77(1):22-32. PubMed ID: 27566127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
